VISION Trial Demonstrates Liquid Biopsy Is Comparable to Tissue Biopsy for NSCLC
Paul K. Paik, MD, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with non–small cell lung cancer harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.
Paul K. Paik, MD, a medical oncologist and clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with nonsmall cell lung cancer (NSCLC) harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.
A unique feature of this trial is that patients could get a liquid biopsy to enroll; tissue biopsy was not a necessary component for enrollment to be included in the VISION trial. Paik says that the data collected and analyzed in the liquid biopsy cohort were similar to that of the tissue biopsy cohort. Rates of response were similar whether patients received a liquid biopsy or tumor biopsy, by both independent and investigator assessments.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
